| Sun, Lingyun |
BEconneCTD-ILD, NCT06572384: A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease |
|
|
| Recruiting | 3 | 440 | Europe, Japan, US, RoW | Belimumab, BENLYSTA, GSK1550188, Placebo | GlaxoSmithKline | Lung Diseases, Interstitial | 10/28 | 12/28 | | |
NCT06716606: A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease |
|
|
| Recruiting | 3 | 225 | RoW | Belimumab | GlaxoSmithKline, ICON plc | Bronchial Diseases | 08/28 | 01/30 | | |
| Recruiting | 2/3 | 240 | Europe, Canada, Japan, US, RoW | EFG PH20 SC, PBO | argenx, argenx BV | Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome | 12/26 | 02/27 | | |
BLISSc-ILD, NCT05878717: A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease |
|
|
| Recruiting | 2/3 | 300 | Europe, Japan, US, RoW | Belimumab, BENLYSTA™, GSK1550188, LymphoStat-B™, BENLYSTATM, GSK1550188, LymphoStat-B™, Placebo | GlaxoSmithKline | Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic | 07/27 | 07/27 | | |
|
NCT04830644: A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome. |
|
|
| Recruiting | 2 | 144 | RoW | Iguratimod, Placebo | Jiangsu Simcere Pharmaceutical Co., Ltd. | Primary Sjögren Syndrome | 04/22 | 06/22 | | |
NCT06250062: A Clinical Study of JS005 in Patients With Ankylosing Spondylitis |
|
|
| Recruiting | 2 | 261 | RoW | Recombinant humanized IL-17A Monoclonal Antibody（JS005）, Placebo（JS005） | Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH | Ankylosing Spondylitis | 02/25 | 10/25 | | |
NCT06222671: A Study to Evaluate 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA) |
|
|
| Not yet recruiting | 2 | 180 | RoW | 608, Placebo | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Axial Spondyloarthritis | 11/25 | 11/25 | | |
NCT05849727: A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis |
|
|
| Recruiting | 2 | 180 | RoW | TQH3821 tablets 200 mg, TQH3821 tablets matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Rheumatoid Arthritis | 06/24 | 12/24 | | |
| Completed | 2 | 456 | Europe, Japan, US, RoW | Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Systemic Lupus Erythematosus | 11/24 | 11/24 | | |
|
|
| Recruiting | 2 | 532 | Europe, Japan, US, RoW | M5049 low dose, Enpatoran, M5049 medium dose, M5049 high dose, Placebo, M5049 very high dose | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Merck Healthcare KGaA | Systemic Lupus Erythematosus | 04/25 | 04/25 | | |
NCT06058078: RY_SW01 Cell Injection Therapy in Active Lupus Nephritis |
|
|
| Recruiting | 2 | 60 | RoW | RY_SW01 cell injection, UC-MSC treatment, Basic treatment, Immunosuppressive drugs | Jiangsu Renocell Biotech Company, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Lupus Nephritis | 12/25 | 12/28 | | |
NCT06717815: Phase Ib/IIa Study for IPG11406 in Patients with Lupus Nephritis |
|
|
| Not yet recruiting | 1/2 | 36 | RoW | IPG11406 | Nanjing Immunophage Biotech Co., Ltd | Lupus Nephritis | 11/25 | 04/26 | | |
NCT04457856: A Study of TJ003234 in Rheumatoid Arthritis Patients |
|
|
| Recruiting | 1 | 63 | RoW | TJ003234 injection | I-Mab Biopharma Co. Ltd. | Rheumatoid Arthritis | 03/23 | 03/23 | | |
NCT06340490: A Study of RJMty19 in Refractory Systemic Lupus Erythematosus (SLE) |
|
|
| Not yet recruiting | 1 | 24 | RoW | RJMty19 (CD19-CAR-DNT cells), Fludarabine, Cyclophosphamide | Guangdong Ruishun Biotech Co., Ltd, RenJi Hospital, Peking University People's Hospital, Changhai Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Systemic Lupus Erythematosus | 12/26 | 12/27 | | |
NCT06462144: IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy |
|
|
| Recruiting | 1 | 36 | RoW | IMPT-514 CART Cell Injection | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Systemic Lupus Erythematosus (SLE), ANCA Associated Vasculitis (AAV), Idiopathic Inflammatory Myopathy (IIM) | 05/25 | 10/26 | | |
| Li, Jie |
NCT03701750: Effect of LMWH on Pregnancy Outcome in Women With Multiple Failures of IVF-ET |
|
|
| Recruiting | 4 | 240 | RoW | Low Molecular Weight Heparin (enoxaparin sodium) | Shenzhen Zhongshan Urology Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Renmin Hospital of Wuhan University | Infertility | 10/21 | 10/22 | | |
| Active, not recruiting | 4 | 640 | RoW | Tenofovir Amibufenamide（TMF）, HS-10234 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Hepatitis B, Chronic | 06/24 | 09/29 | | |
NCT05229809: Clinical Trial of Yiqi Wenyang Jiedu Prescription in the Prevention and Treatment of Postoperative Metastasis and Recurrence of Gastric Cancer |
|
|
| Recruiting | 4 | 212 | RoW | Yiqi Wenyang Jiedu prescription, Simulation agent of Yiqi Wenyang Jiedu prescription | Jie Li | Gastric Carcinoma | 07/23 | 07/24 | | |
NCT03708549: Comparison of Berberine and Metformin for the Treatment for MS in Schizophrenia Patients |
|
|
| Recruiting | 4 | 100 | RoW | Berberine, Metformin | Tianjin Anding Hospital | Schizophrenia, Metabolic Syndrome, Berberine, Metformin | 10/23 | 12/23 | | |
NCT05894694: Survival Benefit of Compound Kushen Injection in the Treatment of Advanced Colorectal Cancer |
|
|
| Recruiting | 4 | 320 | RoW | first-line scheme+compound kushen injection, palliative care group first-line scheme | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | Advanced Colorectal Carcinoma | 12/25 | 12/25 | | |
NCT04875169: Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis |
|
|
| Completed | 3 | 336 | Canada, RoW | Core Treatment Active Experimental: SHR0302 Dose#1, Core Treatment Active Experimental: SHR0302 Dose#2, Core Treatment Placebo Comparator: Placebo, Extension Treatment Active Experimental: SHR0302 Dose#1, Extension Treatment Active Experimental: SHR0302 Dose#2 | Reistone Biopharma Company Limited | Atopic Dermatitis | 08/22 | 05/23 | | |
NCT05525637: Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder |
|
|
| Recruiting | 3 | 1041 | RoW | YZJ-1139 20mg, YZJ-1139 40mg, Placebo | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Insomnia Disorder | 12/24 | 12/24 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure |
|
|
| Recruiting | 3 | 522 | RoW | D-1553 Tablet, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 10/26 | 12/27 | | |
| Not yet recruiting | 3 | 358 | RoW | TQB2450+Anlotinib, TQB2450 placebo + Anlotinib placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Small Cell Lung Cancer Limited Stage | 09/26 | 09/26 | | |
NCT03932136: Decreasing Risk of Psychosis by Sulforaphane (DROPS Trial) |
|
|
| Recruiting | 3 | 300 | RoW | Sulforaphane, ZHIYINGUOSU, Placebo | Shanghai Jiao Tong University School of Medicine, Shanghai Xuhui District Mental Health Center, Shanghai Pudong Nanhui Mental Health Center, Suzhou Psychiatric Hospital, Second Xiangya Hospital of Central South University, Guangzhou Psychiatric Hospital, Shenzhen Fushan Biotech Co., Ltd., Tianjin Anding Hospital, The First Affiliated Hospital of Zhengzhou University, Shenzhen Kangning Hospital | Clinical High Risk Syndrome of Psychosis | 12/25 | 12/26 | | |
NCT06095583: Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) |
|
|
| Recruiting | 3 | 756 | Europe, US, RoW | Tifcemalimab injection, toripalimab injection, Placebo for Tifcemalimab, Placebo for toripalimab | Shanghai Junshi Bioscience Co., Ltd. | Limited-stage Small Cell Lung Cancer (LS-SCLC) | 07/27 | 07/29 | | |
NCT04983043: Efficacy and Safety of QiShen YiQi Dripping Pills in Chronic Heart Failure |
|
|
| Completed | 2 | 228 | RoW | Low dose QiShen YiQi Dripping Pills 3 bags, Low dose group, High dose QiShen YiQi Dripping Pills 3 bags, High dose group, QiShen YiQi Dripping Pills placebo 3 bags, Placebo group | Tasly Pharmaceutical Group Co., Ltd | Chronic Heart Failure With Reduced Ejection Fraction | 11/24 | 11/24 | | |
GMCAII, NCT06221683: Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML |
|
|
| Recruiting | 2 | 500 | RoW | Homoharringtonine, Homoharringtonine injection, Cytarabine, Cytosar, Etoposide, Etoposide injection, Venetoclax, Venclexta, Mitoxantrone hydrochloride liposome, Mitoxantrone hydrochloride liposome injection, Recombinant Human Granulocyte Colony-Stimulating Factor, Recombinant Human Granulocyte Colony-Stimulating Factor Injection, Idarubicin Hydrochloride, Idarubicin hydrochloride injection, Sorafenib, Nexavar, Gilteritinib, Xospata Pill, Avapritinib, AYVAKIT | Children's Hospital of Soochow University | AML, Childhood, Acute Myeloid Leukemia | 12/28 | 12/29 | | |
NCT06316960: Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation |
|
|
| Recruiting | 2 | 50 | RoW | Avapritinib, AYVAKIT, Azacitidine Injection, Azacitidine, Decitabine Injection, Decitabine, Idarubicin Hydrochloride, Idarubicine, Cytarabine, CYTOSAR, Granulocyte Colony-Stimulating Factor, Recombinant Human Granulocyte Colony-Stimulating Factor Injection | Children's Hospital of Soochow University | AML, Childhood, Relapse/Recurrence, Refractory AML, Core Binding Factor Acute Myeloid Leukemia, C-KIT Mutation | 03/26 | 03/27 | | |
NCT06566248: A Clinical Trial to Evaluate the Efficacy and Safety of TQA3810 Tablets in Combination/Non Combination With Nucleoside (Acid) Analogues in Patients With Primary/Treated Chronic Hepatitis B |
|
|
| Recruiting | 2 | 90 | RoW | TQA3810 tablets+NUC, Placebo+NUC | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Hepatitis B | 09/24 | 03/25 | | |
NCT06241781: Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer |
|
|
| Recruiting | 2 | 64 | RoW | GT101 injection, Gemcitabine injection | Grit Biotechnology | Adult | 01/27 | 01/27 | | |
| Recruiting | 2 | 270 | RoW | TQB2102 for injection, TQB2102 for injection combined with Benmelstobart injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Non-Small Cell Lung Cancer | 10/25 | 02/26 | | |
NCT05632861: HuHuangLianzonggan Capsule in Subjects With Nonalcoholic Steatohepatitis: a Phase 2 tRial(HHL-HEPAR) |
|
|
| Recruiting | 2 | 76 | RoW | HuHuangLianzonggan capsule, Experimental group, HuHuangLianzonggan capsule placebo, Placebo group | Tasly Pharmaceutical Group Co., Ltd | NASH | 12/24 | 12/24 | | |
TQB3909-Ib/II-02, NCT05959694: A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . |
|
|
| Recruiting | 1/2 | 107 | RoW | TQB3909 tablet | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/25 | 06/26 | | |
CIBI343A101, NCT05458219: A First-in-human Study of IBI343 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 470 | US, RoW | IBI343 | Innovent Biologics (Suzhou) Co. Ltd., Innovent Biologics, Inc., TigerMed | Locally Advanced Unresectable or Metastatic Solid Tumors | 12/25 | 12/25 | | |
NCT06325267: Clinical Characteristics of Primary Liver Cancer |
|
|
| Recruiting | N/A | 1000 | RoW | | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Primary Liver Cancer | 08/24 | 08/24 | | |
NCT06325254: Clinical Characteristics of Metabolic Associated Fatty Liver Disease |
|
|
| Recruiting | N/A | 3000 | RoW | | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Metabolic Associated Fatty Liver Disease, Clinical Features | 08/24 | 08/24 | | |
NCT06524505: Efficacy, Tolerability, and Cognitive Effects of Deep Transcranial Magnetic Stimulation for Bipolar Depression |
|
|
| Recruiting | N/A | 100 | RoW | deep Transcranial Magnetic Stimulation (dTMS) -active, deep Transcranial Magnetic Stimulation (dTMS) -sham | Tianjin Anding Hospital | Bipolar Depression | 10/24 | 11/24 | | |
| Not yet recruiting | N/A | 60 | RoW | Endostar, S1 | Peking University Third Hospital, Mianyang Central Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing Cancer Hospital, Peking University International Hospital, China-Japan Friendship Hospital, The fifth medical center of PLA general hospital, Second Hospital of Shanxi Medical University, Hiser Medical Center of Qingdao, Guangxi Ruikang Hospital, GEM flower hospital of Liaohe oil field, Tang-Du Hospital, Third Affiliated Hospital of Guizhou Medical University, Liuzhou Worker's Hospital, The Affiliated Hospital of Xuzhou Medical University, Dalian municipal central hospital affiliated of dalian medical university | Radiotherapy Side Effect | 01/22 | 01/23 | | |
| Recruiting | N/A | 630 | Europe, US, RoW | ROX index algorithm | Hospital Universitari Vall d'Hebron Research Institute | Acute Hypoxemic Respiratory Failure | 12/24 | 06/25 | | |
NCT04564573: Antidepressant Treatments and Cognitive Function of Bipolar Patients |
|
|
| Recruiting | N/A | 124 | RoW | | Tianjin Anding Hospital | Bipolar Disorder, Cognition | 07/22 | 10/22 | | |
NCT04562324: Efficacy of Electroencephalography (EEG) Neurofeedback (NF) for the Treatment of Anxiety Disorder |
|
|
| Recruiting | N/A | 60 | RoW | SSRI or SNRI or benzodiazepines or tricyclic antidepressants or other antidepressants or antipsychotics or other sedative-hypnotics, Neurofeedback system | Tianjin Anding Hospital | Anxiety Disorder, Healthy | 10/22 | 11/23 | | |
NCT04497493: Efficacy of Transcranial Direct Current Stimulation (tDCS) for the Treatment of Major Depressive Disorder |
|
|
| Recruiting | N/A | 75 | RoW | Transcranial Direct Current Stimulation (tDCS)-active, active, Transcranial Direct Current Stimulation (tDCS)-sham, sham | Tianjin Anding Hospital | Major Depressive Disorders | 10/22 | 03/23 | | |
NCT06000137: The Comparison of the Analgesic Effects of Dezocine and Sufentanil in Patient-controlled Analgesia After Laryngectomy |
|
|
| Completed | N/A | 129 | RoW | Dezocine, Sufentanil injection, sufentanil, Flurbiprofen, Granisetron Injection, granisetron | Eye & ENT Hospital of Fudan University | Patient-controlled Analgesia | 01/23 | 01/23 | | |
NCT02972398: N-Acetyl Cysteine Supplementation in Therapy Refractory Major Depressive Disorders |
|
|
| Recruiting | N/A | 200 | RoW | N-acetylcysteine, YiWeiShi, placebo comparator of N-acetylcysteine | Tianjin Anding Hospital | Major Depressive Disorders | 07/23 | 09/23 | | |
NCT04971148: Correlation of Peak Tidal Inspiratory Flow Measured Before and After Extubation in Adult Patients With Hypoxemia |
|
|
| Terminated | N/A | 5 | Europe, US | HFNC flow set at patient peak tidal inspiratory flow, HFNC flow set at 1.33 times of patient peak tidal inspiratory flow, HFNC flow set at 1.67 times of patient peak tidal inspiratory flow, HFNC flow set at 2 times of patient peak tidal inspiratory flow | Rush University Medical Center, Hospital Vall d'Hebron | Hypoxemic Respiratory Failure | 08/23 | 08/23 | | |
| Recruiting | N/A | 76 | RoW | Amisulpride, Solian, Olanzapine, Oulanning | Tianjin Anding Hospital | BPSD, Amisulpride, Olanzapine, Dementia of the Alzheimer Type | 12/23 | 05/24 | | |
| Recruiting | N/A | 500 | US | | COPD Foundation, Viatris Inc. | COPD | 12/24 | 07/25 | | |
| Recruiting | N/A | 50 | RoW | Multifaceted Intervention | Third Affiliated Hospital, Sun Yat-Sen University, Sir Run Run Shaw Hospital, The Second Affiliated Hospital of Hunan University of Chinese Medicine, Longgang Orthopedics Hospital of Shenzhen, The First People's Hospital of Hefei, Dongguan Eighth People's Hospital, The Third People's Hospital of Longgang District Shenzhen | Fragility Fracture | 06/25 | 06/27 | | |
NCT06269419: Study of Natural Course Progression of Diabetic Retinopathy |
|
|
| Recruiting | N/A | 200 | RoW | | Jie Li | Biomarkers of Diabetic Retinopathy | 01/29 | 01/29 | | |
NCT06300918: A Clinical Trial to Evaluate the Time Point of Anti-VEGF Pretreatment of PDR Based on Intraoperative FFA |
|
|
| Recruiting | N/A | 60 | RoW | Time | Jie Li | The Condition of Fundus Neovascularization | 08/25 | 08/25 | | |
NCT05932095: TCM Daoyin in the Treatment of Patients With Anxiety State |
|
|
| Recruiting | N/A | 20 | RoW | TCM Daoyin, Qigong, Health education | Shanghai University of Traditional Chinese Medicine, Shanghai Mental Health Center | Anxiety State | 03/24 | 08/24 | | |
NCT06228703: The Effects of Different Flow Settings on Lung Impedance |
|
|
| Recruiting | N/A | 26 | US | High-flow nasal cannula device with flow setting at 40 L/min or higher, HFNC flow at 40 L/min or higher | Rush University Medical Center | Healthy | 11/24 | 12/24 | | |
NCT05589337: Baduanjin Training for Depression and Anxiety Patients |
|
|
| Recruiting | N/A | 120 | RoW | Baduanjin, Eight-section Brocade, Health education | Shanghai University of Traditional Chinese Medicine, Shanghai Mental Health Center | Depression Symptoms, Anxiety Symptoms | 06/24 | 12/24 | | |
| Recruiting | N/A | 92 | RoW | Nervio-X | Ruijin Hospital, Tianjin Anding Hospital, Shanghai East Hospital | Major Depressive Disorder | 05/25 | 05/25 | | |
NCT05626309: Clinical Trial of Qizhu Yuling Prescription in the Prevention and Treatment of Esophagus Cancer |
|
|
| Recruiting | N/A | 310 | RoW | Qizhu Yuling Prescription, Placebo, Simulation agent of Qizhu Yuling Prescription | Jie Li | Esophagus Cancer | 08/24 | 11/24 | | |
NCT06561295: Optimal Timing for Spontaneous Breathing Trials |
|
|
| Recruiting | N/A | 348 | US | Later Morning Timing of Spontaneous Breathing Trials | Rush University Medical Center | Respiration, Artificial, Weaning | 12/25 | 06/26 | | |
NCT05766449: Risk Factors for Hepatic Inflammation, Fibrosis and Prognosis in Patients With CHB and NAFLD |
|
|
| Recruiting | N/A | 1000 | RoW | | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Chronic Hepatitis b, Non-alcoholic Fatty Liver Disease | 03/27 | 05/27 | | |
NCT05940480: TCM Daoyin Therapy in Individuals At-risk for COPD |
|
|
| Recruiting | N/A | 60 | RoW | TCM Daoyin, Qigong, Health education | Shanghai University of Traditional Chinese Medicine, Changzheng Community Health Service Center of Putuo District, Shanghai | Chronic Obstructive Pulmonary Disease, Lung Diseases, Obstructive | 06/27 | 12/27 | | |
NCT05937178: Real-world Study Optimizing Nucleotide-analogues |
|
|
| Recruiting | N/A | 20000 | RoW | ETV/TAF/TDF/TMF/IFN, ETV/TAF/TDF/TMF | Huashan Hospital, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, Beijing YouAn Hospital, Peking University People's Hospital, Peking University First Hospital, Xiamen Hospital of Traditional Chinese Medicine, First Affiliated Hospital of Fujian Medical University, LanZhou University, Third Affiliated Hospital, Sun Yat-Sen University, First Affiliated Hospital of Guangxi Medical University, The Affiliated Hospital Of Guizhou Medical University, Hainan General Hospital, Hebei Medical University Third Hospital, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Henan Provincial People's Hospital, The Second Affiliated Hospital of Harbin Medical University, Tongji Hospital, Wuhan Union Hospital, China, Renmin Hospital of Wuhan University, Central South University, Xiangya Hospital of Central South University, The First Hospital of Jilin University, the Second Hospital of Nangjing, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Hospital of Xuzhou Medical University, The First Affiliated Hospital of Nanchang University, Shengjing Hospital, Qingdao Sixth People's Hospital, Shandong Provincial Hospital Affiliated to Shandong First Medical University, The Second Hospital of Shandong University, The First Affiliated Hospital of Shanxi Medical University, Tang-Du Hospital, First Affiliated Hospital Xi'an Jiaotong University, Ruijin Hospital, West China Hospital, Tianjin Second People's Hospital, First Affiliated Hospital of Xinjiang Medical University, The First People's Hospital of Yunnan, Shulan (Hangzhou) Hospital, Zhejiang University, Southwest Hospital, China, The Second Affiliated Hospital of Chongqing Medical University, Sichuan Provincial People's Hospital | Hepatitis B, Chronic | 01/29 | 01/29 | | |
EFLRWR, NCT05132218: Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer |
|
|
| Recruiting | N/A | 180 | RoW | Ensatinib, BD-EN-IV002 | Beijing Cancer Hospital, Betta Pharmaceuticals Co., Ltd. | ALK Positive, NSCLC Stage IIIB, NSCLC Stage IV | 10/22 | 10/24 | | |
| Zhu, Dalong |
NCT06381323: The Clinical Efficacy and Safety of Finerenone in the Treatment of Primary Aldosteronism |
|
|
| Recruiting | 4 | 55 | RoW | Finerenone, Nifedipine | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Primary Aldosteronism, Finerenone, Mineralocorticoid Receptor Antagonist | 03/27 | 04/27 | | |
NCT04373967: Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes |
|
|
| Recruiting | 3 | 424 | RoW | Victoza®., Metformin Hydrochloride, TQZ2451 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Type 2 Diabetes | 12/21 | 12/21 | | |
NCT05628311: A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise |
|
|
| Completed | 3 | 319 | RoW | placebo, IBI362 | Innovent Biologics (Suzhou) Co. Ltd. | Type 2 Diabetes | 10/23 | 05/24 | | |
NCT06339086: Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes |
|
|
| Not yet recruiting | 3 | 478 | NA | Semaglutide Injection, Semaglutide Injection(Ozempic®), Ozempic®, Metformin, Glucophage® | Chengdu Brilliant Pharmaceutical Co., Ltd. | Type 2 Diabetes Mellitus | 08/25 | 12/25 | | |
NCT05680155: A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients |
|
|
| Active, not recruiting | 3 | 211 | RoW | Ecnoglutide, XW003, Placebo | Hangzhou Sciwind Biosciences Co., Ltd. | T2DM, Type 2 Diabetes Mellitus | 10/24 | 10/24 | | |
| Completed | 2/3 | 547 | RoW | Supaglutide injection, placebo injection | Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. | Type2 Diabetes | 06/23 | 08/23 | | |
NCT05063253: A Study of TG103 Injection in Overweight/Obese Subjects With Type 2 Diabetes |
|
|
| Not yet recruiting | 2 | 208 | NA | TG103, Administered SC, Placebo | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Type 2 Diabetes Mellitus | 03/24 | 03/24 | | |
NCT06546436: The Safety and Efficiency of a Single Dose of CARC-101C in Patients With Autoimmune Type 1 Diabetes Mellitus |
|
|
| Not yet recruiting | 1 | 12 | RoW | CARC-101C | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Carcell Biopharma Ltd. | Autoimmune Type 1 Diabetes Mellitus(T1DM) | 11/25 | 05/27 | | |
NCT05168072: Weight Loss Effects of M-health App in Obesity Multidisciplinary Outpatient Clinic |
|
|
| Enrolling by invitation | N/A | 80 | RoW | m-Health app, conventional outpatient obesity management | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Obesity, m-Health, NAFLD | 12/22 | 12/23 | | |
NCT04833192: Evaluation of New Diagnostic Indicator of Subclinical Hypercortisolism |
|
|
| Recruiting | N/A | 202 | RoW | experimental group | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Adrenal Incidentaloma, Subclinical Hypercortisolism | 04/23 | 12/23 | | |
NCT05484817: Early Assessment of Impaired Cardiac Function in Patients With Diabetes Mellitus |
|
|
| Recruiting | N/A | 300 | RoW | Assessment of cardiovascular risk factor, endocrine hormones and related biomarker | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Diabetes Mellitus, Left Ventricular Dysfunction | 09/23 | 09/23 | | |
NCT05826080: Effect of Adrenocorticotropic Hormone Stimulation During Adrenal Vein Sampling in Primary Aldosteronism |
|
|
| Recruiting | N/A | 59 | RoW | | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Primary Aldosteronism, Aldosterone-Producing Adenoma, Idiopathic Hyperaldosteronism | 10/23 | 09/24 | | |
NCT05560997: Metabolic Subtypes of Non-Alcoholic Fatty Liver Disease |
|
|
| Recruiting | N/A | 1000 | RoW | 10-year ASCVD risk estimation | Yan Bi | Non-Alcoholic Fatty Liver Disease, Machine Learning | 10/24 | 06/25 | | |
NCT05357456: Performances on Cognitive Functions and Brain Function and Follow-up After Different Treatments in Patients With Autonomous Cortisol Secretion: a Single-center, Prospective, Observational Study |
|
|
| Recruiting | N/A | 62 | RoW | Cognitive function assessment; functional magnetic resonance imaging, fMRI, laparoscopic adrenal surgery | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Autonomous Cortisol Secretion, Adrenal Incidentaloma, Non-functioning Adrenal Adenomas | 10/24 | 10/26 | | |
| Du, Juan |
NCT06476210: The Safety and Efficacy of BDL(Bedaquiline Plus Delamanid Plus Linezolid) Regimen in Subjects With Pulmonary Infection of Multi-drug Resistant Tuberculosis (MDR-TB) or Rifampicin-Resistant Tuberculosis (RR-TB) |
|
|
| Recruiting | 4 | 45 | RoW | BDL regimen | Beijing Chest Hospital, Public Health Clinical Medical Center of Chengdu, Wuhan Institute for Tuberculosis Control, Changsha Central Hospital, Anhui Chest Hospital, Hunan Chest Hospital, Shandong Public Health Clinical Center | Pulmonary Tuberculosis | 06/25 | 06/26 | | |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
PROSPECT, NCT05306223: A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China |
|
|
| Recruiting | 4 | 212 | RoW | Bedaquiline, SIRTURO, Levofloxacin, Linezolid, Cycloserine, Clofazimine, Pyrazinamide, Protionamide | Beijing Chest Hospital | Tuberculosis, Multidrug-Resistant | 08/25 | 08/25 | | |
NCT04300114: A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy |
|
|
| Terminated | 3 | 5 | RoW | Fluzoparib, SHR3162, Placebo | Jiangsu HengRui Medicine Co., Ltd. | Metastatic Pancreatic Cancer | 02/22 | 02/22 | | |
INSPIRE-BDLL, NCT06649721: Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort |
|
|
| Not yet recruiting | 3 | 120 | RoW | bedaquiline, BDQ, B, delamanid, DLM, D, linezolid, LZD, L, Levofloxacin, LFX, Clofazimine, CFZ, C | Huashan Hospital, Beijing Chest Hospital | Drug-resistant Tuberculosis, Pulmonary Tuberculosis, Rifampin-resistant Tuberculosis | 06/27 | 06/27 | | |
INSPIRE-CODA, NCT06081361: Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort |
|
|
| Recruiting | 3 | 186 | RoW | Bedaquiline, BDQ, Delamanid, DLM, Contezolid, CZD, Levofloxacin, LFX, Moxifloxacin, MFX, Clofazimine, CFZ, Linezolid, LZD, Cycloserine, CS, Prothionamide, Pto, Pyrazinamide, PZA, Para-Aminosalicylic Acid, PAS, Ethambutol, EMB | Beijing Chest Hospital, National Medical Center for Infectious Diseases | Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis | 10/26 | 12/26 | | |
NCT05634564: Concurrent Chemoradiotherapy Combined With Immunotherapy in Patients With Potentially Resectable Pancreatic Cancer |
|
|
| Recruiting | 2 | 62 | RoW | Tislelizumab, Gemcitabine, Nab paclitaxel, Hypofractionated radiotherapy with simultaneous integrated boost | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Pancreatic Carcinoma | 04/23 | 12/23 | | |
NCT06305104: Clinical Trial to Explore the Skin Test Dosage of EEC in People Aged 18 to 65 Years Old and the Safety and Preliminary Efficacy in People Aged 3 to 75 Years Old. |
|
|
| Recruiting | 2 | 420 | RoW | 2.5μg/ml EEC, 5μg/ml EEC, 5 unit（U） EC | Chengdu CoenBiotech Co., Ltd, Beijing Chest Hospital, Capital Medical University, Wuhan Institute for Tuberculosis Control, The Public Health Clinical Center of Chengdu, Xuzhou Infectious Disease Hospital, Jiangsu Province Centers for Disease Control and Prevention, Changde First People's Hospital | Tuberculosis | 05/24 | 06/24 | | |
NCT06389760: Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer |
|
|
| Recruiting | 2 | 57 | RoW | Nimotuzumab, Taixinsheng, mFOLFIRINOX, GX | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Pancreatic Cancer | 09/26 | 09/26 | | |
NCT06224036: Clinical Study of JDB0131 Benzenesulfonate Tablets in Patients With Drug-sensitive Pulmonary Tuberculosis |
|
|
| Recruiting | 2 | 52 | RoW | JDB0131, Delamanid, Ethylpyrazine rifampicide (II) | Beijing Chest Hospital, West China Hospital, Wuhan Pulmonary Hospital (Wuhan Institute For Tuberculosis Control) | Drug-resistant Tuberculosis | 03/24 | 03/24 | | |
PAAG, NCT05493995: A Study of Penpulimab and Anlotinib Plus Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Cancer. |
|
|
| Completed | 2 | 66 | RoW | Penpulimab, AK105, Anlotinib, Nab paclitaxel, Gemcitabine | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pancreatic Neoplasms | 05/24 | 05/24 | | |
CZ-WM01, NCT05979948: A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia |
|
|
| Recruiting | 2 | 60 | RoW | Zanubrutinib, Bendamustine, Rituximab | Shanghai Changzheng Hospital, RenJi Hospital, Huashan Hospital, Shanghai 6th People's Hospital, Huadong Hospital | Waldenström's Macroglobulinemia | 04/25 | 12/25 | | |
RCT-PAAG, NCT06051851: Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer |
|
|
| Recruiting | 2 | 177 | RoW | Penpulimab, Anlotinib, Nab paclitaxel, Gemcitabine | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Pancreatic Adenocarcinoma Metastatic | 07/25 | 07/26 | | |
NCT05594797: Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM |
|
|
| Recruiting | 2 | 100 | RoW | Human BCMA Targeted T Cells Injection, BCMA CAR-T | Hrain Biotechnology Co., Ltd., Shanghai Changzheng Hospital, First Affiliated Hospital of Wenzhou Medical University | Multiple Myeloma | 07/25 | 07/27 | | |
NCT04941937: Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM |
|
|
| Recruiting | 2 | 90 | RoW | Selinexor, ATG-010/KPT-330, Thalidomide, fǎn yìng tíng, Lenalidomide, Revlimid, An xian, Pomalidomide, POMALYST, Dexamethasone, Dex | Juan Du | Multiple Myeloma | 12/25 | 12/25 | | |
| Recruiting | 1/2 | 20 | RoW | GC012F injection | Shanghai Changzheng Hospital, Gracell Biotechnology Shanghai Co., Ltd. | Multiple Myeloma | 07/23 | 07/23 | | |
NCT06235229: A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 110 | RoW | GC012F | Gracell Biotechnologies Ltd. | Multiple Myeloma | 03/26 | 06/26 | | |
NCT05302648: To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM |
|
|
| Active, not recruiting | 1 | 18 | RoW | Human Derived anti-BCMA CAR-T Injection, BCMA CAR-T | Hrain Biotechnology Co., Ltd., Shanghai Changzheng Hospital | Multiple Myeloma | 12/24 | 12/25 | | |
CIBI343A101, NCT05458219: A First-in-human Study of IBI343 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 470 | US, RoW | IBI343 | Innovent Biologics (Suzhou) Co. Ltd., Innovent Biologics, Inc., TigerMed | Locally Advanced Unresectable or Metastatic Solid Tumors | 12/25 | 12/25 | | |
NCT05412329: Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple Myeloma |
|
|
| Recruiting | 1 | 9 | RoW | GC012F injection | Shanghai Changzheng Hospital, Gracell Biotechnology Shanghai Co., Ltd. | Multiple Myeloma | 06/24 | 06/24 | | |
NCT06407947: Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma |
|
|
| Recruiting | 1 | 10 | RoW | Chimeric antigen receptor modified T cells Infusion, Single Group Assignment | Shanghai Changzheng Hospital, CARsgen Therapeutics Co., Ltd. | Multiple Myeloma | 06/27 | 06/27 | | |
| Active, not recruiting | 1 | 20 | RoW | Experimental: CAR-T cells Infusion, Single Group Assignment | Shanghai Changzheng Hospital, CARsgen Therapeutics Co., Ltd. | Multiple Myeloma, Primary Plasma Cell Leukemia | 07/25 | 07/25 | | |
NCT06718270: a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia |
|
|
| Recruiting | 1 | 24 | RoW | CAR-T cells Infusion | Shanghai Changzheng Hospital, CARsgen Therapeutics Co., Ltd. | Relapsed/Refractory Multiple Myeloma, Relapsed/Refractory Plasma Cell Leukemia | 01/27 | 12/27 | | |
NCT05840107: Study of FasT CAR-T GC012F Injection NDMM Patients |
|
|
| Recruiting | 1 | 18 | RoW | GC012F injection | Shanghai Changzheng Hospital, Gracell Biotechnology Shanghai Co., Ltd. | Multiple Myeloma | 09/25 | 09/25 | | |
